Indicators of neuroprotection with galantamine

Brain Research Bulletin

Volumn 64, Issue 6, 2005, Pages 519-524

  Geerts, Hugo ^a  

^a In Silico Biosciences   (United States)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Galantamine; Neuroprotective agents

Indexed keywords

ALPHA BUNGAROTOXIN; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; PROTEIN BCL 2; RIVASTIGMINE; TACRINE; TALSACLIDINE;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; CELL SURVIVAL; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENILE PLAQUE; STRESS; UPREGULATION;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; GALANTAMINE; GLUTAMIC ACID; HUMANS; INDICATORS AND REAGENTS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 11444262026     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2004.11.002     Document Type: Article

References (33)

1. E. Arias, E. Alés, N. Gabilan, M. Cano-Abad, M. Villarroya, A. García, and M.G. López Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors Neuropharmacology 46 2004 103 114
2. N. Bodick, F. Forette, D. Hadler, R.J. Harvey, P. Leber, I.G. McKeith, P.J. Riekkinen, M.N. Rossor, P. Scheltens, S. Shimohama, R. Spiegel, S. Tanaka, L.J. Thal, Y. Urata, P. Whitehouse, and G. Wilcock Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group Alzheimer Dis. Assoc. Disord. 11 Suppl. 3 1997 50 53
3. G.M. Bores, F.P. Huger, and W. Petko Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galantamine J. Pharmacol. Exp. Ther. 277 1996 728 738
4. S. Capsoni, G. Ugolini, A. Comparini, F. Ruberti, N. Berardi, and A. Cattaneo Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice Proc. Natl. Acad. Sci. 97 12 2000 6826 6831
5. S. Capsoni, S. Giannotta, and A. Cattaneo Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice Proc. Natl. Acad. Sci. 99 19 2002 12432 12437
6. P. Davidsson, K. Blennow, N. Andreasen, B. Eriksson, L. Minthon, and C. Hesse Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease Neurosci. Lett. 300 3 2001 157 160
7. P. Davies, and A.J. Maloney Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 1976 1403
8. K.L. Davis, R.C. Mohs, D. Marin, D.P. Purohit, D.P. Perl, M. Lantz, G. Austin, and V. Haroutunian Cholinergic markers in elderly patients with early signs of Alzheimer disease JAMA 281 15 1999 1401 1406
9. A. Fisher, Z. Pittel, R. Haring, N. Bar-Ner, M. Kliger-Spatz, N. Natan, I. Egozi, H. Sonego, I. Marcovitch, and R. Brandeis M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy J. Mol. Neurosci. 20 3 2003 349 356
10. H. Geerts, C. Grantham, Guillaumat Pierre-Olivier, Nini Bode, Katelijne Anciaux, and Sachak Sohel Functional studies of brain level and AChE inhibition with galantamine and donepezil in rats, mice and rabbits Neurobiol. Aging 25 S2 2004 187
11. E. Hellstrom-Lindahl, M. Mousavi, R. Ravid, and A. Nordberg Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients Neurobiol. Dis. 15 2 2004 351 360
12. C. Hock, A. Maddalena, A. Raschig, F. Muller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Muller-Thomsen, W. Oertel, M. Wienrich, A. Signorell, C. Gonzalez-Agosti, and R.M. Nitsch Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Abeta 42 in patients with Alzheimer's disease Amyloid 10 1 2003 1 6
13. C. Ikonomidou, and L. Turski Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1 6 2002 383 386
14. Ahmadul Kadir, Michaela Grut, Anders Wall, Elka Stefanova, Ove Almkvist, Gunnar Blomqvist, Birgitta Strandberg, Bo Eriksson, Bengt Långström, and Agneta Nordberg Long-term effects of galantamine treatment on brain cortical acetylcholinesterase inhibition and nicotinic receptors in Alzheimer patients visualized by PET Springfield Symposium Montreal 2004
15. T. Kihara, S. Shimohama, H. Sawada, J. Kimura, T. Kume, H. Kochiyama, T. Maeda, and A. Akaike Nicotinic receptor stimulation protects neurons against β-amyloid toxicity Ann. Neurol. 42 1997 159 163
16. T. Kihara, S. Shimohama, M. Urushitani, H. Sawada, J. Kimura, T. Kume, T. Maeda, and A. Akaike Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity Brain Res. 792 1998 331 334
17. D.E. Kuhl, S. Minoshima, K.A. Frey, N.L. Foster, M.R. Kilbourn, and R.A. Koeppe Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex Ann. Neurol. 48 3 2000 391 395
18. L. Letenneur, S. Larrieu, and P. Barberger-Gateau Alcohol and tobacco consumption as risk factors of dementia: a review of epidemiological studies Biomed. Pharmacother. 58 2 2004 95 99
19. A. Nordberg, E. Hellstrom-Lindahl, M. Lee, M. Johnson, M. Mousavi, R. Hall, E. Perry, I. Bednar, and J. Court Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw) J. Neurochem. 81 3 2002 655 658
20. M.J. O'Neill, D. Bleakman, D.M. Zimmerman, and E.S. Nisenbaum AMPA receptor potentiators for the treatment of CNS disorders Curr. Drug Targets CNS Neurol. Disord. 3 3 2004 181 194
21. L. Parnetti, S. Amici, A. Lanari, C. Romani, C. Antognelli, N. Andreasen, L. Minthon, P. Davidsson, H. Pottel, K. Blennow, and V. Gallai Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors Neurol. Sci. 23 Suppl. 2 2002 S95 S96
22. M.A. Raskind, E.R. Peskind, L. Truyen, P. Kershaw, and C.V. Damaraju The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial Arch. Neurol. 61 2 2004 252 256
23. M. Samochocki, A. Hoffle, A. Fehrenbacher, R. Jostock, J. Ludwig, C. Christner, M. Radina, M. Zerlin, C. Ullmer, E.F. Pereira, H. Lubbert, E.X. Albuquerque, and A. Maelicke Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors J. Pharmacol. Exp. Ther. 305 3 2003 1024 1036
24. M.D. Santos, M. Alkondon, and E.F. Pereira The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system Mol. Pharmacol. 61 2002 1222 1234
25. H. Shinotoh, A. Aotsuka, K. Fukushi, S. Nagatsuka, N. Tanaka, T. Ota, S. Tanada, and T. Irie Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET Neurology 56 3 2001 408 410
26. R. Siman, T.K. McIntosh, K.M. Soltesz, Z. Chen, R.W. Neumar, and V.L. Roberts Proteins released from degenerating neurons are surrogate markers for acute brain damage Neurobiol. Dis. 16 2 2004 311 320
27. M. Sobrado, J.M. Roda, M.G. Lopez, J. Egea, and A.G. Garcia Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation Neurosci. Lett. 365 2 2004 132 136
28. R.G. Stern, R.C. Mohs, M. Davidson, J. Schmeidler, J. Silverman, E. Kramer-Ginsberg, T. Searcey, L. Bierer, and K.L. Davis A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration Am. J. Psychiatry 151 1994 390 396
29. Y. Takada, A. Yonezawa, T. Kume, H. Katsuki, S. Kaneko, H. Sugimoto, and A. Akaike Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons J. Pharmacol. Exp. Ther. 306 2 2003 772 777
30. T. Thomsen, and H. Kewitz Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo Life Sci. 46 1990 1553 1558
31. L. Truyen Long-term effects of treatment with galantamine on patients with Alzheimer's disease Res. Pract. Alzheimers Dis. 8 2004 1 4
32. M.H. Tuszynski, and A. Blesch Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease Prog. Brain Res. 146 2004 441 449
33. P.J. Whitehouse, B. Kittner, M. Roessner, M. Rossor, M. Sano, L. Thal, and B. Winblad Clinical trial designs for demonstrating disease-course-altering effects in dementia Alzheimer Dis. Assoc. Disord. 12 4 1998 281 294